BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+6.86%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.54B
AUM Growth
+$4.54B
(+1.7%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$39.2M |
| 2 |
Immunocore
IMCR
|
$38.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$36.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
$20M |
| 5 |
Edgewise Therapeutics
EWTX
|
$17.7M |
Top Sells
| 1 |
Incyte
INCY
|
$35.5M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$29.9M |
| 3 |
Intuitive Surgical
ISRG
|
$25.6M |
| 4 |
Boston Scientific
BSX
|
$20M |
| 5 |
Cencora
COR
|
$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Technology | 0.01% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $315M | 6.94% | 571,039 -7,835 | -1% | -$4.32M |
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $310M | 6.84% | 7,853,198 | – | – |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $229M | 5.04% | 1,820,000 | – | – |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $221M | 4.86% | 676,367 -91,780 | -12% | -$29.9M |
|
5
Abbott
ABT
$231B
| $213M | 4.69% | 1,564,022 +7,893 | +0.5% | +$1.07M |
|
6
Stryker
SYK
$150B
| $212M | 4.67% | 535,089 -31,508 | -6% | -$12.5M |
|
|
7
Intuitive Surgical
ISRG
$170B
| $206M | 4.54% | 378,728 -47,018 | -11% | -$25.6M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $197M | 4.33% | 441,610 +28,539 | +7% | +$12.7M |
|
|
9
Boston Scientific
BSX
$156B
| $190M | 4.18% | 1,765,194 -185,826 | -10% | -$20M |
|
10
Revolution Medicines
RVMD
$7.1B
| $168M | 3.71% | 4,579,300 +205,000 | +5% | +$7.54M |
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $119M | 2.63% | 3,590,150 +75,000 | +2% | +$2.49M |
|
|
12
Incyte
INCY
$16.5B
| $107M | 2.36% | 1,570,333 -521,447 | -25% | -$35.5M |
|
|
13
Akero Therapeutics
AKRO
$3.74B
| $106M | 2.33% | 1,985,272 +734,606 | +59% | +$39.2M |
|
14
Scholar Rock
SRRK
$3.14B
| $104M | 2.3% | 2,947,295 +440,405 | +18% | +$15.6M |
|
15
Medtronic
MDT
$119B
| $80.3M | 1.77% | 921,043 -17,312 | -2% | -$1.51M |
|
|
16
Immunocore
IMCR
$1.62B
| $76.6M | 1.69% | 2,441,830 +1,220,036 | +100% | +$38.3M |
|
17
DexCom
DXCM
$29.5B
| $75.1M | 1.66% | 860,828 -203,280 | -19% | -$17.7M |
|
18
Edwards Lifesciences
EW
$47.8B
| $69.5M | 1.53% | 889,077 -82,892 | -9% | -$6.48M |
|
19
Insulet
PODD
$23.9B
| $68.8M | 1.52% | 219,013 -52,273 | -19% | -$16.4M |
|
20
Celldex Therapeutics
CLDX
$1.47B
| $67.3M | 1.48% | 3,307,569 +235,954 | +8% | +$4.8M |
|
21
Becton Dickinson
BDX
$55.3B
| $54.6M | 1.2% | 316,732 -27,579 | -8% | -$4.75M |
|
22
Beam Therapeutics
BEAM
$1.66B
| $49.1M | 1.08% | 2,889,288 +493,358 | +21% | +$8.39M |
|
|
23
Thermo Fisher Scientific
TMO
$186B
| $46M | 1.01% | 113,544 +49,312 | +77% | +$20M |
|
24
Penumbra
PEN
$10.6B
| $44.7M | 0.98% | 174,050 -30,467 | -15% | -$7.82M |
|
25
UnitedHealth
UNH
$281B
| $44.4M | 0.98% | 142,296 -22,446 | -14% | -$7M |
|